Next Article in Journal / Special Issue
From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis
Previous Article in Journal
Hydrogel Microwell Arrays Allow the Assessment of Protease-Associated Enhancement of Cancer Cell Aggregation and Survival
Article Menu

Export Article

From the third issue of 2017, Microarrays has changed its name to High-Throughput.

Open AccessReview

Improving Pathological Assessment of Breast Cancer by Employing Array-Based Transcriptome Analysis

Deptartment of Pediatrics, Semmelweis University, Budapest H-1083, Hungary
Research Laboratory of Pediatrics and Nephrology, Hungarian Academy of Sciences, Budapest H-1083, Hungary
Author to whom correspondence should be addressed.
Microarrays 2013, 2(3), 228-242;
Received: 29 July 2013 / Revised: 17 August 2013 / Accepted: 22 August 2013 / Published: 29 August 2013
(This article belongs to the Special Issue Clinical Applications of Microarrays)
PDF [211 KB, uploaded 29 August 2013]


Breast cancer research has paved the way of personalized oncology with the introduction of hormonal therapy and the measurement of estrogen receptor as the first widely accepted clinical biomarker. The expression of another receptor—HER2/ERBB2/neu—was initially a sign of worse prognosis, but targeted therapy has granted improved outcome for these patients so that today HER2 positive patients have better prognosis than HER2 negative patients. Later, the introduction of multigene assays provided the pathologists with an unbiased assessment of the tumors’ molecular fingerprint. The recent FDA approval of complete microarray pipelines has opened new possibilities for the objective classification of breast cancer samples. Here we review the applications of microarrays for determining ER and HER2 status, molecular subtypes as well as predicting prognosis and grade for breast cancer patients. An open question remains the role of single genes within such signatures. Openly available microarray datasets enable the execution of an independent cross-validation of new marker and signature candidates. In summary, we review the current state regarding clinical applications of microarrays in breast cancer molecular pathology. View Full-Text
Keywords: breast cancer; microarray; molecular subtype; prognosis; prediction; biomarker breast cancer; microarray; molecular subtype; prognosis; prediction; biomarker
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Mihály, Z.; Győrffy, B. Improving Pathological Assessment of Breast Cancer by Employing Array-Based Transcriptome Analysis. Microarrays 2013, 2, 228-242.

Show more citation formats Show less citations formats

Article Metrics

Article Access Statistics



[Return to top]
Microarrays EISSN 2076-3905 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top